Safety and Efficacy of Different Formulations of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Study Identifier
192024-048
CT.gov Identifier
NCT01099774
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Glaucoma - Other
  • Ocular Hypertension
    • Study Drug
  • Bimatoprost 0.03% Formulation B Ophthalmic Solution
  • Bimatoprost 0.03% Ophthalmic Solution
    • Phase
    Phase 3
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Patient has ocular hypertension or glaucoma in both eyes * Requires IOP-lowering therapy in each eye
    Exclusion Criteria:
    * Active or recurrent eye disease that would interfere with interpretation of study data in either eye * History of any eye surgery or laser in either eye within 6 months * Required chronic use of other eye medications during the study * Anticipated wearing of contact lenses during the study. * Intermittent use of oral, intramuscular, or intravenous corticosteroids within 21 days

    Protocol Summary

    This study will evaluate the safety and efficacy of bimatoprost 0.03% formulation B ophthalmic solution with LUMIGAN® (bimatoprost ophthalmic solution 0.03%) once daily for 12 weeks in patients with glaucoma or ocular hypertension

    Study Locations

    Location
    Status
    Location
    Newport Beach, California, United States
    Status
    Not applicable